ALK and non-small cell lung carcinoma: BFAST is an ongoing multi-center, open-label, multi-cohort study evaluating the relationship between blood-based NGS detection of actionable genetic alterations including ALK fusions and the activity of targeted therapies and immunotherapy in patients with treatment-naïve advanced NSCLC [42].